Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Accounts Payables (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Accounts Payables readings, the most recent being $1.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 20.64% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Dec 2025, down 20.64%, and an annual FY2025 reading of $1.0 million, down 20.64% over the prior year.
  • Accounts Payables hit $1.0 million in Q4 2025 for Lisata Therapeutics, up from $619000.0 in the prior quarter.
  • The five-year high for Accounts Payables was $2.4 million in Q4 2023, with the low at $556000.0 in Q3 2024.
  • Median Accounts Payables over the past 3 years was $900500.0 (2025), compared with a mean of $1.1 million.
  • The sharpest move saw Accounts Payables tumbled 57.62% in 2024, then grew 11.33% in 2025.
  • Year by year, Accounts Payables stood at $2.4 million in 2023, then crashed by 46.96% to $1.3 million in 2024, then dropped by 20.64% to $1.0 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $1.0 million, $619000.0, and $782000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.